Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change

被引:0
|
作者
Young, Carolyn A. [1 ,2 ]
Chaouch, Amina [3 ]
Mcdermott, Christopher J. [4 ]
Al-Chalabi, Ammar [5 ,6 ]
Chhetri, Suresh K. [7 ]
Talbot, Kevin [8 ]
Malaspina, Andrea [9 ]
Mills, Roger [1 ,2 ]
Tennant, Alan [10 ]
机构
[1] Walton Ctr NHS Fdn Trust, Lower Lane, Liverpool L9 7LJ, England
[2] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool, England
[3] Greater Manchester Ctr Clin Neurosci, Salford, England
[4] Sheffield Inst Translat Neurosci, Sheffield, England
[5] Kings Coll London, Maurice Wohl Clin Neurosci Inst, Dept Basic & Clin Neurosci, London, England
[6] Kings Coll Hosp London, Dept Neurol, London, England
[7] Lancashire Teaching Hosp, Preston, England
[8] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England
[9] UCL Queen Sq Inst Neurol, London, England
[10] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England
关键词
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; Trajectories of Outcome in Neurological Conditions-ALS; Rasch; outcome measurement; disability; CLINICALLY IMPORTANT DIFFERENCE; ORDINAL SCALES; TRIALS; SCORES; RASCH;
D O I
10.1080/21678421.2024.2322539
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundThe Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score is a widely used measure of functional status in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS), but recent evidence has raised doubts about its validity. The objective was to examine the measurement properties of the ALSFRS-R, aiming to produce valid measurement from all 12 scale items.MethodLongitudinal ALSFRS-R data were collected between 2013-2020 from 1120 people with ALS recruited from 35 centers, together with other scales in the Trajectories of Outcomes in Neurological Conditions-ALS (TONiC-ALS) study. The ALSFRS-R was analyzed by confirmatory factor analysis (CFA), Rasch Analysis (RA) and Mokken scaling.ResultsNo definite factor structure of the ALSFRS-R was confirmed by CFA. RA revealed the raw score total to be invalid even at the ordinal level because of multidimensionality; valid interval level subscale measures could be found for the Bulbar, Fine-Motor and Gross-Motor domains but the Respiratory domain was only valid at an ordinal level. All four domains resolved into a single valid, interval level measure by using a bifactor RA. The smallest detectable difference was 10.4% of the range of the interval scale.ConclusionA total ALSFRS-R ordinal raw score can lead to inferential bias in clinical trial results due to its non-linear nature. On the interval level transformation, more than 5 points difference is required before a statistically significant detectable difference can be observed. Transformation to interval level data should be mandatory in clinical trials.
引用
收藏
页码:400 / 409
页数:10
相关论文
共 26 条
  • [1] Clinimetrics: Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R)
    Lee, Michael
    McCambridge, Alana
    JOURNAL OF PHYSIOTHERAPY, 2018, 64 (04) : 269 - 270
  • [2] Assessing the Measurement Properties of the Self-Administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): A Rasch Analysis
    Mehdipour, Ava
    Teshler, Lizabeth
    Dal Bello-Haas, Vanina
    Richardson, Julie
    Beauchamp, Marla
    Turnbull, John
    Chum, Marvin
    Johnston, Wendy
    O'Connell, Colleen
    Luth, Westerly
    Kuspinar, Ayse
    PHYSICAL THERAPY, 2023, 103 (11):
  • [3] Spanish adaptation of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)
    Salas Campos, Teresa
    Rodriguez-Santos, Francisco
    Esteban, Jesus
    Cordero Vazquez, Pilar
    Mora Pardina, Jesus S.
    Cano Carmona, Alejandra
    AMYOTROPHIC LATERAL SCLEROSIS, 2010, 11 (05): : 475 - 477
  • [4] Validity and reliability of the Russian version of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)
    Brylev, Lev
    Demeshonok, V. S.
    Ataulina, A. I.
    Kovalchuk, M. O.
    Druzhinin, D. S.
    Guekht, A. B.
    NEUROLOGICAL SCIENCES, 2024, 45 (01) : 187 - 189
  • [5] Adaptation to Turkish and Reliability Study of the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)
    Koc, Filiz
    Balal, Mehmet
    Demir, Turgay
    Alparslan, Z. Nazan
    Sarica, Yakup
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2016, 53 (03): : 229 - 233
  • [6] Validity and reliability of the Russian version of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)
    Lev Brylev
    V. S. Demeshonok
    A. I. Ataulina
    M. O. Kovalchuk
    D. S. Druzhinin
    A. B. Guekht
    Neurological Sciences, 2024, 45 : 187 - 189
  • [7] Discriminant ability of the amyotrophic lateral sclerosis functional rating scale revised (ALSFRS-R) to detect dysarthria in individuals with amyotrophic lateral sclerosis
    Donohue, Cara
    Wiele, Lauren
    Anderson, Amber
    DiBiase, Lauren
    Croft, Kayla
    Wymer, James
    Plowman, Emily
    MUSCLE & NERVE, 2022, 66 : S21 - S22
  • [8] Arabic adaptation and validation of the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R): Egyptian study
    Rashed, Hebatallah R.
    Tork, Mohamed A.
    Soliman, Radwa
    Serag, Rehab
    Fahmy, Nagia
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2021, 22 (3-4) : 220 - 222
  • [9] Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) by Domain and Individual Items
    Palumbo, Joseph M.
    Takei, Koji
    Tsuda, Kikumi
    Liu, Shawn
    NEUROLOGY, 2017, 88
  • [10] Cumulative Distribution of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Scores in a Phase 3 Study of Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Assessment
    Takei, Koji
    Palumbo, Joseph M.
    Tsuda, Kikumi
    Liu, Shawn
    NEUROLOGY, 2017, 88